Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition
International Journal of Molecular Sciences · 10.09.2024 · 25 (18) · 9782
DOI: 10.3390/ijms25189782 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.09.2024. Verfasst von Patrycja Marzęta-Assas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecure S.A., 101 Żwirki i Wigury St., 02-089 Warsaw, Poland. Hauptthemen laut MEDLINE: Arginase, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for Research and Development, European Funds Smart Growth and European Regional Development Fund, DIMUNO: “Development of new cancer therapies based on selective antitumor immunomodulators”.
Abstract (Originalsprache)
Arginases are key enzymes that hydrolyze L-arginine to urea and L-ornithine in the urea cycle. The two arginase isoforms, arginase 1 (ARG1) and arginase 2 (ARG2), regulate the proliferation of cancer cells, migration, and apoptosis; affect immunosuppression; and promote the synthesis of polyamines, leading to the development of cancer. Arginases also compete with nitric oxide synthase (NOS) for L-arginine, and their participation has also been confirmed in cardiovascular diseases, stroke, and inflammation. Due to the fact that arginases play a crucial role in the development of various types of diseases, finding an appropriate candidate to inhibit the activity of these enzymes would be beneficial for the therapy of many human diseases. In this review, based on numerous experimental, preclinical, and clinical studies, we provide a comprehensive overview of the biological and physiological functions of ARG1 and ARG2, their molecular mechanisms of action, and affected metabolic pathways. We summarize the recent clinical trials’ advances in targeting arginases and describe potential future drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecure S.A., 101 Żwirki i Wigury St., 02-089 Warsaw, Poland.
- Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland.
ORCID-Profile: Damian Jacenik
Förderung
- National Centre for Research and Development
- European Funds Smart Growth and European Regional Development Fund
- DIMUNO: “Development of new cancer therapies based on selective antitumor immunomodulators”
Zitieren
APA
Marzęta-Assas, P., Jacenik, D., & Zasłona, Z. (2024). Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition. International Journal of Molecular Sciences, 25(18), 9782. https://doi.org/10.3390/ijms25189782
Vancouver
Marzęta-Assas P, Jacenik D, Zasłona Z. Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition. International Journal of Molecular Sciences. 2024;25(18):9782. doi:10.3390/ijms25189782
BibTeX
@article{MarztaAssas2024,
author = {Marzęta-Assas, Patrycja and Jacenik, Damian and Zasłona, Zbigniew},
title = {Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {18},
pages = {9782},
doi = {10.3390/ijms25189782}
}
EUVIMED